Journal article
P641 – A cost-utility analysis of enfortumab vedotin and pembrolizumab versus nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma
Authors
Cheung D; Bernardino R; May J; Papasideris M; Bremner K; Fleshner N; Lalani A-K; Ong M; Wong W; Wallis C
Journal
European Urology, Vol. 87, ,
Publisher
Elsevier
Publication Date
March 1, 2025
DOI
10.1016/j.eururo.2025.09.3070
ISSN
0302-2838